Clinical Trial Update: An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase I/II study evaluating two schedules of dasatinib plus decitabine in accelerated or blastic phase chronic myeloid leukemia; study terminated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Leukemia

Drugs mentioned

• Dacogen (decitabine)
• Sprycel (dasatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-10-22